Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Free Cash Flow (2016 - 2025)

Creative Medical Technology Holdings has reported Free Cash Flow over the past 15 years, most recently at -$1.9 million for Q4 2025.

  • Quarterly Free Cash Flow rose 0.61% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.9 million through Dec 2025, down 10.47% year-over-year, with the annual reading at -$5.9 million for FY2025, 10.47% down from the prior year.
  • Free Cash Flow was -$1.9 million for Q4 2025 at Creative Medical Technology Holdings, down from -$1.2 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$222139.0 in Q2 2021 and troughed at -$3.8 million in Q1 2023.
  • The 5-year median for Free Cash Flow is -$1.2 million (2023), against an average of -$1.5 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 2137.93% in 2021 and later surged 76.65% in 2024.
  • Tracing CELZ's Free Cash Flow over 5 years: stood at -$1.2 million in 2021, then tumbled by 209.23% to -$3.6 million in 2022, then soared by 47.23% to -$1.9 million in 2023, then dropped by 2.88% to -$1.9 million in 2024, then grew by 0.61% to -$1.9 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$1.9 million, -$1.2 million, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.